Depression is the third leading cause of disability in the world. Depressive symptoms may
be reduced within several weeks after the start of conventional antidepressants, but …

Background In the past two decades, subanaesthetic doses of ketamine have been
demonstrated to have rapid and sustained antidepressant effects, and accumulating …

Introduction Ketamine's efficacy in depressive disorders has been established in several
controlled trials. The aim of the present study was to determine whether or not ketamine …

Objective: The authors conducted a systematic review and meta-analysis of ketamine and
other N-methyl-d-aspartate (NMDA) receptor antagonists in the treatment of major …

Newer antidepressants are needed for the many individuals with major depressive disorder
(MDD) that do not respond adequately to treatment and because of a delay of weeks before …

Background Racemic ketamine and esketamine have demonstrated rapid antidepressant
effects. We aimed to review the efficacy and safety of racemic and esketamine for …

Major depression is a common, recurrent mental illness that affects millions of people
worldwide. Recently, a unique fast neuroprotective and antidepressant treatment effect has …

Monoaminergic neurotransmitter (serotonin, norepinephrine and dopamine) mechanisms of
disease dominated the research landscape in the pathophysiology and treatment of major …

The burden of depressive disorders and the frequent inadequacy of their current
pharmacological treatments are well established. The anaesthetic and hallucinogenic drug …

The role of ketamine anesthesia in the prehospital, emergency department and operating
theater settings is not well defined. A nonsystematic review of ketamine was performed by …